Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. - Wikidata - wikimedia - TriplyDB

Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B.

Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B.

http://www.wikidata.org/entity/Q45858690

about

New developments in the management of moderate-to-severe hemophilia B Emerging and future therapies for hemophilia Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters Achieving and maintaining an optimal trough level for prophylaxis in haemophilia: the past, the present and the future Fc-fusion technology and recombinant FVIII and FIX in the management of the hemophilias Once-weekly prophylactic dosing of recombinant factor IX improves adherence in hemophilia B Aspects of prophylactic treatment of hemophilia Extravascular FIX and coagulation The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy The History of Clotting Factor Concentrates Pharmacokinetics Hemophilia Care in the Pediatric Age.Clinical utility and patient perspectives on the use of extended half-life rFIXFc in the management of hemophilia B.Management of hemophilia in Korea: the past, present, and future.Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial Regulation of immune responses by the neonatal fc receptor and its therapeutic implications AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice.Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies.Issues in assessing products for the treatment of hemophilia - the intersection between efficacy, economics, and ethics.Recombinant Factor IX Fc Fusion Protein Maintains Full Procoagulant Properties and Exhibits Prolonged Efficacy in Hemophilia B Mice.Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial.Physical activity in individuals with haemophilia and experience with recombinant factor VIII Fc fusion protein and recombinant factor IX Fc fusion protein for the treatment of active patients: a literature review and case reports.Human cell lines for biopharmaceutical manufacturing: history, status, and future perspectives.Prophylactic efficacy of BeneFIX vs Alprolix in hemophilia B mice.Novel products for haemostasis - current status.Changing paradigm of prophylaxis with longer acting factor concentrates.Emerging drugs for hemophilia B.Current management of hemophilia B: recommendations, complications and emerging issues.Research in haemophilia B--approaching the request for high evidence levels in a rare disease.Individualizing prophylaxis in hemophilia: a review.Role of enhanced half-life factor VIII and IX in the treatment of haemophilia.The current status of prophylactic replacement therapy in children and adults with haemophilia.Longer-acting clotting factor concentrates for hemophilia.A systematic review of definitions and reporting of bleeding outcome measures in haemophilia.New and Emerging Agents for the Treatment of Hemophilia: Focus on Extended Half-Life Recombinant Clotting Proteins.Health-related quality of life assessment in haemophilia patients on prophylaxis therapy: a systematic review of results from prospective clinical trials.New products for the treatment of haemophilia.Eftrenonacog Alfa: A Review in Haemophilia B.Modulating immunogenicity of factor IX by fusion to an immunoglobulin Fc domain: a study using a hemophilia B mouse model.Current and future prospects for hemophilia gene therapy.Haemophilia treatment in 2030.

P2860

Q26751323-AA6520CD-8AE3-4B8D-918E-048480697C5A Q26781143-4C87A408-9234-4EB2-8F24-359D64677F3F Q26801319-12029672-EC18-4899-8763-28D6182B826F Q26853631-F2B67F36-82AA-437B-9D12-106E2B23C8A5 Q27014771-31AF9E99-1FE3-4614-9DCA-69C562FFD70D Q28078281-C9A3DDAA-2AE9-4A27-BBA1-64972BF9448A Q28078562-94CD7D71-1DF3-4F81-9A1B-8AD83FBDF98C Q28079369-2E539DFB-257D-4A44-B40C-3928FF739298 Q28257521-5D0F2D77-6ED8-4773-89A9-56803BB197AF Q30235127-5B373C48-CEF9-4576-967B-EEF49322A112 Q33737259-2FD24219-DDC1-4347-A75F-FB553BF7CA55 Q34045763-D0F1E6D5-7CB7-46B1-B067-E95B078CF343 Q34302456-774CF91C-DDB5-46D4-9F7C-1F859E7CDB3B Q34737483-E4DFBA6D-0414-42F6-BB3B-5E9368CD1F2D Q34818194-C6C1A011-D638-487D-ABDB-6AE9EE52D7DB Q35153203-4D37C2BF-A440-4589-BC8D-CD24559E0FD3 Q35684362-D400414A-3E80-4F5E-96C7-00A2239BE4A3 Q35766551-47FBD2F2-2B16-48D6-9FA1-755C1DE63344 Q35913495-B47F90EB-E311-4C18-B119-8A74B69AC8FF Q36780134-B9FA1D15-D9C3-4A15-BBB9-8FEA3DD12C9A Q37320598-B651B2C3-4A47-42D2-900D-437B60210C5B Q37494846-C69BAF44-C8C4-4573-95D5-853B42B8AFFA Q37623821-47562BD0-C288-4B9A-AE71-F8991C598B8D Q38206849-958CE527-D966-4508-BECC-B830E5F7CA57 Q38206858-37ED91A0-EC95-48AC-AA07-7C84175646DC Q38237476-7EC6B18E-46C9-437E-9EE7-9804EE3F6CD4 Q38238972-59DFE227-C0DE-4186-BEA0-4D729F08BC89 Q38286306-D00DF3CA-8DE1-40FD-8907-CE66DFDFDFF4 Q38323857-C5494CED-646E-486D-94FF-F25A305501F3 Q38371071-BDCFB3F8-C0DE-4299-9FF3-40BFA0A6951F Q38394904-64FF05DE-1C0F-44EB-9716-C74778CE7669 Q38543283-E8E9B1F9-FB01-41E9-9108-B64FB4C7D57A Q38548021-199F27AC-FEA7-4621-8C9B-441785AA106E Q38574414-1294FDF7-445C-4FED-932F-3F5186D78FF2 Q38590269-292F79EA-BFE9-44B3-9862-81E2EBB32DDC Q38604626-0A0D7F33-8D0D-4B79-9590-F71C2A6B8199 Q38711095-5E2B205A-224D-4D4A-96FF-2C1C640191D1 Q38760836-0B15BFF9-1C7F-40B8-9068-080A8D12A4CA Q38827606-4088890D-C6F3-4601-B1FE-340F221F697F Q38842671-D055CE3A-BAB5-48FE-AD21-BB6071D7606D

P2860

Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B.

http://www.wikidata.org/entity/Q45858690

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B.

@en

Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B.

@nl

type

label

Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B.

@en

Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B.

@nl

prefLabel

Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B.

@en

Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B.

@nl

P1433

Q45858690-887514AC-A202-4EE8-8114-6C78DBC71613

P1476

Q45858690-01227020-3A2F-4517-BD13-461CCA0AE667

P2093

Q45858690-03F9BAF8-887C-4494-B541-F8CB08AC366D

Q45858690-09619CB9-686F-4CF6-B6AB-151B99FAB646

Q45858690-134048D0-CF34-4559-9AEF-DE913960A68F

Q45858690-1CBAE009-CCC3-413E-8755-FDFE5165701C

Q45858690-28FE5CDC-38F8-46CB-AB17-008CEC069A6B

Q45858690-29922C5C-7FBE-444B-88E7-49E71B368AB4

Q45858690-332F8AD7-63EB-4330-8B77-0B170A37BE27

Q45858690-33CB1536-A28B-4F23-8592-30C168843CDA

Q45858690-389E3D71-3970-4250-A6A7-31D8EA29646F

Q45858690-38FEB94E-D9EB-4396-8864-D22168B67544

P304

Q45858690-9946D25C-4E0F-4809-89EE-54B53CC0F89E

P31

Q45858690-F7ADCDB2-F4A7-40A8-ADB0-BA85D6377B0C

P356

Q45858690-CC46AA02-2B2B-4EDC-B364-B715C7D7BE01

P407

Q45858690-E174DA06-1C4E-42AE-9AE4-E560CB40BD6F

P433

Q45858690-FCFDD726-E6EF-4775-B963-55647F237308

P478

Q45858690-6DB85E4C-054D-4374-B1BB-F697E0B39FD0

P50

Q45858690-5144308A-A5BC-4425-8638-427374E152DB

Q45858690-7E00F7CB-F008-4313-93F5-FF7D52AC1F08

P577

Q45858690-0FE18531-F35A-41FF-9CF8-1BA1C348A2A6

P5875

Q45858690-E7BF4EA2-B553-482A-810B-4FF7BD294122

P698

Q45858690-6DF024EB-10E1-41C3-95A2-A06024DC26C9

P921

Q45858690-1C380168-654D-458F-9BE0-8BEF02A7E2B9

Q45858690-8DDB5C0F-E2A7-44A5-A7BC-2C2B651E836A

Q45858690-E9498A99-4A90-4625-B927-7111FACCAAD9

P356

P1433

The New England Journal of Medicine

P1476

Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B.

@en

P2093

Alison Innes

http://www.w3.org/2001/XMLSchema#string

Alvin Luk

http://www.w3.org/2001/XMLSchema#string

Aoife Brennan

http://www.w3.org/2001/XMLSchema#string

B-LONG Investigators

http://www.w3.org/2001/XMLSchema#string

David Perry

http://www.w3.org/2001/XMLSchema#string

Glenn F Pierce

http://www.w3.org/2001/XMLSchema#string

Gloria Vigliani

http://www.w3.org/2001/XMLSchema#string

Godfrey C Chan

http://www.w3.org/2001/XMLSchema#string

Haiyan Jiang

http://www.w3.org/2001/XMLSchema#string

Jaya Goyal

http://www.w3.org/2001/XMLSchema#string

P304

2313-2323

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1305074

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

369

http://www.w3.org/2001/XMLSchema#string

P50

Geoffrey A Allen

Raymond Siu-Ming Wong

P577

2013-12-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260796451

http://www.w3.org/2001/XMLSchema#string

P698

24304002

http://www.w3.org/2001/XMLSchema#string

P921

Coagulation factor IX